<DOC>
	<DOC>NCT01753557</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of MP-424 with PEG-IFN Alfa-2a and RBV in patients with genotype 1 hepatitis C, who are naïve to its treatment or relapsed after previous treatment.</brief_summary>
	<brief_title>Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Genotype 1 CHC treatmentnaïve or relapsers (patient who relapsed after previous treatment) Able and willing to follow contraception requirements Cirrhosis of the liver or hepatic failure Hepatitis B surface antigenpositive or HIV (Human Immunodeficiency Virus) antibodiespositive History of, or concurrent hepatocellular carcinoma History of, or concurrent depression, schizophrenia, or suicide attempt in the past Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pegasys</keyword>
</DOC>